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ABSTRACT
CONTEXT AND OBJECTIVE: Worldwide, there is no single strategy for optimal management of patients 
with ASCUS (atypical squamous cells of undetermined significance) cytology reports. The objective of this 
study was to determine the kind of clinical management conducted among women with a first ASCUS 
Pap smear report. 
DESIGN AND SETTING: Prospective single cohort study at a cervical pathology unit in Santiago, Chile. 
METHODS: This was an epidemiological, descriptive, observational and quantitative follow-up study on a 
cohort of women with ASCUS cytological reports. 
RESULTS: In the screening phase, 92,001 cervical cytological smears were collected in primary healthcare 
clinics. In the diagnostic phase, all women with a first ASCUS report were selected (n = 446). These women 
were asked to undergo the Pap test again and it was found that 301 women had normal results, 62 
women had abnormal results and 83 did not repeat the test. In the diagnostic confirmation phase, the 
62 women with abnormal results underwent colposcopy and, from these results, 58 of them underwent 
a biopsy. The results from the biopsies showed that 16 women had negative histological reports, 13 had 
CIN 1 and 29 had CIN 2+. In the treatment phase, the 42 women with lesions underwent a variety of 
treatments, according to the type of lesion. In the post-treatment phase, cytological and colposcopic 
monitoring was instituted.
CONCLUSION: The clinical management consisted of traditional management of screening, diagnosis, 
diagnostic confirmation, treatment and post-treatment monitoring. 
RESUMO
CONTEXTO E OBJETIVO: Mundialmente, não existe estratégia única para o gerenciamento ideal de pa-
cientes com laudos de citologia ASCUS (atypical squamous cells of undetermined significance). O objetivo 
do estudo foi determinar o tipo de gerenciamento clínico realizado em mulheres com o primeiro laudo 
de Papanicolaou ASCUS.
DESENHO E LOCAL: Estudo prospectivo de coorte única em uma unidade de patologia cervical em 
Santiago, Chile. 
MÉTODOS: Estudo epidemiológico, descritivo, observacional e quantitativo de seguimento de um grupo 
de mulheres com laudos de citologia ASCUS.
RESULTADOS: Na fase de rastreamento, 92.001 relatórios de citologia cervical foram coletados nos ambu-
latórios da rede pública de saúde. Na fase de diagnóstico, foi selecionada a totalidade de mulheres com 
relatórios citológicos de ASCUS (n  =  446). Essas mulheres foram submetidas a repetição do exame de 
Papanicolaou, obtendo-se 301 mulheres com resultados normais, 62 mulheres com resultados anormais 
e 83 que não repetiram o exame. Na fase de confirmação de diagnóstico, as 62 mulheres com resultados 
anormais foram submetidas a colposcopia e, considerando-se os resultados obtidos, 58 foram submetidas 
a biópsia. Os resultados das biópsias mostraram 16 mulheres com laudos histológicos negativos, 13 com 
NIC 1 e 29 com NIC 2 +. Na fase terapêutica, as 42 mulheres com lesões foram submetidas a diversos 
tratamentos de acordo com o tipo de lesão. Para a fase pós-tratamento, foi instituído um sistema de mo-
nitoramento citocolposcópico.
CONCLUSÃO: As condutas clínicas tiveram gestão tradicional de rastreamento, diagnóstico, confirmação 
diagnóstica, tratamento e acompanhamento pós-tratamento.
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INTRODUCTION
Atypical squamous cells of undetermined significance (ASCUS) 
are the most prevalent abnormality in cervical cytological eval-
uations. This is a category of uncertain morphology and is at 
the limit between normal and abnormal cytological interpreta-
tions.1,2 The clinical significance of ASCUS is considered to be 
indeterminate, which means that there is controversy or debate 
regarding its clinical management, given that there is no single 
choice for optimal treatment.3,4
In Chile, the Ministry of Health (Minsal) has developed clini-
cal guidelines that contain two clinical decision diagrams called 
the “algorithm for conveying the first atypical Pap test accord-
ing to Bethesda 2001 classification, to a specialist or cervical 
pathology unit (CPU)” and the “algorithm for diagnostic con-
firmation”.5,6 These diagrams contain the steps for diagnostic 
confirmation and treatment of cervical atypia and are based on 
the first consensus guidelines for management of these cervical 
atypia, published by Wright et al.,7 which were based on the mul-
ticenter study titled Atypical Squamous Cells of Undetermined 
Significance/Low-grade Squamous Intraepithelial Lesion Triage 
Study (ALTS).8 
In Chile there is a paucity of scientific evidence on the clin-
ical management of women with cervical atypia.9 In addition, 
the national conveyance algorithm and national diagnostic con-
firmation algorithm are supported by evidence derived from 
English-speaking countries.10-13 This situation makes it appro-
priate and relevant to conduct studies that generate current and 
local epidemiological evidence for managing atypical cervical 
cytology. This challenge is consistent with the objectives set by 
Minsal, which has the goal of generating clinical algorithms sup-
ported by national scientific evidence.14 
OBJECTIVE
The objective of this study was to determine the kind of clini-
cal management performed among females with a first ASCUS 
report, diagnosed between 2008 and 2009 and followed up at the 
Cervical Pathology Unit of the Barros Luco Hospital (primary 
care hospital base) within the Southern Metropolitan Healthcare 
Area of Santiago, Chile.
METHODS
An epidemiological study was performed consisting of descrip-
tive, prospective, observational and quantitative follow-up was 
conducted on a cohort of women with ASCUS cytology reports 
who formed part of the National Program for Research and 
Control of Cervical Cancer in Chile. 
From 2008 to 2009, 92,001 exfoliative cervical cytological 
smears were collected by professionals at primary healthcare clin-
ics (PHCs) in the southern metropolitan area of Santiago, Chile 
(Table 1). These smears were processed by means of the conven-
tional technique of Pap sampling and were classified in accor-
dance with the national classification system, which is equivalent 
to that of Bethesda 2001 as detailed below. This was done in the 
Cytology Laboratory of the Pathology Department of the Barros 
Luco Hospital in Santiago, Chile.15,16 Subsequently, these records 
were filed in the Diagnostics Archive of Minsal’s Cyto-Expert 
System (a cytological-histological database). At this time, all the 
ASCUS reports were selected (n = 555) (Table 1). 
Selection criteria were applied to these patients, so as to select 
patients without previous uterine pathological conditions, with-
out previous cervical procedures and with normal Pap results 
over a three-year period prior to the beginning of the study. 
After making this selection, a cohort of 446 women with ASCUS 
reports was obtained and these women were monitored for a 
period of three years, or until resolution of the case or until loss 
from the follow up. They were treated at the Cervical Pathology 
Unit of the Barros Luco Hospital.
For data gathering, the Cyto-Expert database and the patient’s 
clinical records were used. 
The variables studied included the women’s ages at the time 
when ASCUS was identified; the type and number of cytological, 
colposcopic and histological results; and treatments instituted.
The national classification was used for coding the cytologi-
cal variable. This is equivalent to that of Bethesda 2001 and uses 
the following categories: negative for intraepithelial lesion or 
malignancy (Neg); atypical squamous cells (ASC); atypical squa-
mous cells of undetermined significance (ASCUS); low-grade 
squamous intraepithelial lesion (LSIL); and high-grade squa-
mous intraepithelial lesion (HSIL).
Table 1. Screening phase: exfoliative cervical cytological 
examinations from the primary care health services of Santiago, 
Chile, 2008 - 2009
Cytology Result Number %
Negative cytology
Satisfactory 79,521 86.43
Less than optimal 4,062 4.41
Inadequate 6,679 7.26
Atypical
Atypical squamous cells of undetermined 
significance (ASCUS)
555 0.60
Atypical squamous cells cannot exclude 
high-grade SIL (ASC-H)
150 0.16
Atypical glandular cells of undetermined 
significance (AGC-US)
41 0.04
Atypical glandular cells suggestive of 
adenocarcinoma in situ 
13 0.01
Positive cytology 
Low-grade Pap 486 0.53
High-grade Pap 444 0.48
Invasive cancer 50 0.05
Total    92,001 99.94
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The following definitions were used in coding the col-
poscopic variable. Normal colposcopy (Neg) was defined as neg-
ative colposcopic findings of intraepithelial lesions; colposcopic 
intraepithelial lesions (IEL) were defined as colposcopic find-
ings showing a squamous cervical lesion; colposcopic human 
papillomavirus (HPV) was defined as presence of lesions in 
the cervix probably caused by HPV; squamous cell carcinoma 
(SCC) was defined as the presence of visual characteristics 
of this disease; and undetermined colposcopy was defined as 
uncertainty in the definition of the diagnosis. In addition, we 
included the variable of colposcopic HPV + IEL, defined as 
presence of both of these conditions.
Finally, cervical intraepithelial neoplasia (CIN) codes were 
used in coding the histological variable. These were classified 
as: negative for intraepithelial lesion or malignancy (Neg); mild 
cervical intraepithelial neoplasia (CIN 1); moderate cervical 
intraepithelial neoplasia (CIN 2); severe cervical intraepithelial 
neoplasia (CIN 3); carcinoma “in situ” (CIS); and squamous cell 
carcinoma (SCC).
Descriptive statistics were used for data analysis. These iden-
tified the number, type and outcome of the procedures per-
formed, and also the time intervals between the first atypical 
ASCUS result and i) diagnosis; ii) diagnostic confirmation; iii) 
treatment; and iv) post-treatment evaluation.
In order to present the information obtained in the investi-
gation graphically, a tree diagram of conditional probability was 
constructed. In this diagram, a circle was used to represent cer-
vical cytological analysis, an octagon for losses from the follow-
up, a square for colposcopic analysis and a box for biopsy. In this 
design, the number indicated the quantity of patients and the 
classifications, the examination results or the clinical or surgi-
cal procedures.
This study was approved by the Andres Bello University 
Ethics Committee and the Scientific Ethics Committee of the 
Southern Metropolitan Healthcare Service in Santiago, Chile.
RESULTS
The study population consisted of 446 women with ASCUS 
cytology reports. The average age of the women was 37.74 years, 
with a minimum age of 17 and maximum age of 88. The clini-
cal management performed was based on the national clinical 
algorithms.
The follow-up was presented in five phases: screening, diag-
nosis, diagnostic confirmation, treatment and post-treatment 
evaluation.
In the first phase (screening), 92,001 Pap tests were collected. 
A result consisting of ASCUS was found in 0.60% of this popu-
lation (n = 555) (Table 1). A cohort of 446 women was obtained 
from this group by applying the selection criteria of our study.
In the second phase (diagnosis), atypical Pap tests should 
be repeated at the same PHC within six months, in accordance 
with the national algorithms. Out of the total of 446 women, 
83 did not come back for cytological smear collection within a 
period of one year and were considered to have been lost from 
the follow-up. The remaining women obtained the following 
results: i) 301  patients were negative for intraepithelial lesions 
or malignancy (Neg) and, in accordance with the national algo-
rithms, continued with the scheme of repeating Pap screening 
every three years; and ii) 62 women whose cytological findings 
were divided into: Neg (n = 8), Neg + HPV (n = 4), ASC (n = 8), 
LSIL (n = 8), HSIL (n = 21), inadequate smear with inflammatory 
cytological findings (n = 1) and SCC (n = 2). This last result was 
obtained through biopsy. These 62 women with cytohistological 
alterations and/or clinical symptoms were referred to the CPU to 
elucidate the cytological diagnosis (Figure 1).
In the third phase (diagnostic confirmation), two procedures 
performed at the CPU were used: colposcopy and biopsy. A col-
poscopic examination was carried out on 62 women and showed 
the following results: negative colposcopy (Neg) (n  =  13), IEL 
(n = 30), IEL + HPV (n = 9), SCC (n = 2), Neg + HPV (n = 5) 
and undetermined colposcopic findings (n = 3). Given the results 
observed, biopsies were carried out on 58 women during the same 
procedure, at the same time. Four women presented normal col-
poscopic results and therefore did not undergo this procedure. 
In most of the women, negative colposcopic findings (n = 13) were 
correlated with negative histological findings. The result was con-
firmed in the cases of seven women (negative for cervical intraepi-
thelial neoplasia) and two others were found to have CIN 1. HPV 
was present in the remaining four women (Figure 2).
Among the patients diagnosed with IEL (n  =  39), the col-
poscopic results coincided with the histological results in 33 
cases, and these results were: CIN 1 (n = 9), CIN 2 (n = 14), CIN 
3 (n = 9) and CIS (n = 1). The remaining six were negative for 
intraepithelial neoplasia (Neg). 
The patients diagnosed with squamous cell carcinoma 
(n = 2) were confirmed histologically to have stage IB2 cervical 
cancer (SCC).
The patients whose colposcopy was defined as Neg + HPV 
(n = 5) received confirmation of the presence of HPV from the 
histological result.
Finally, the cases of undetermined colposcopic findings (n = 3) 
were defined by means of histological examinations, such that two 
cases were negative for lesions (Neg) and one presented CIN 1.
In summary, the results from the 58 biopsies performed were 
divided into: negative for intraepithelial lesions (Neg, n =  16), 
low-grade lesion (CIN 1, n = 13) and high-grade lesion (CIN 2 +, 
n =  29). Presence of HPV was detected in 39 histological exami-
nations (Figure 2).
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In the fourth phase (treatment), some negative biopsy results 
(n = 12) and the CIN 1 + HPV result of a pregnant woman were 
excluded, giving a total of 45 women who were under treatment. 
For therapeutic resolution of these cases, one of the following 
procedures was used: cervical cryosurgery, surgical conization 
(CKC), hysterectomy (HT) or chemotherapy and radiother-
apy (CT + RT).
Patients with mild lesions (CIN 1) underwent cryother-
apy (n  =  4) and needle biopsy (n  =  7). Those with moderate 
and severe lesions (CIN 2/3) underwent cold-knife cone biopsy 
(n = 26) and hysterectomy (n = 1). The patient with CIS (n = 1) 
underwent hysterectomy and the patients with stage IB2 cervical 
cancer (n = 2) underwent chemotherapy and radiotherapy. One 
patient presented CIN 1 + HPV contained in a cervical polyp 
(n = 1), which was removed (Figure 3).
Finally, in the fifth phase (post-treatment follow-up), three 
procedures were carried out: colposcopy, cytological sam-
ple collection and histological sample collection (if necessary). 
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HPV 4 
ASC
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LSIL
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21
SCC
2
Inammatory
1
Biopsy
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follow-up 83
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446 ♀
Figure 1. Diagnostic stage: repeated Pap smears in women with first ASCUS reports. 
ASCUS, atypical squamous cells of undetermined significance; Neg, negative for neoplastic cells; HPV, human papillomavirus; ASC, atypical squamous 
cells; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma; Inflammatory 
specimens; CPU, cervical pathology unit.
Figure 2. Diagnostic confirmation stage: histological and colposcopic follow-up results in women with ASCUS.
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Neg, negative for intraepithelial lesion; IEL, intraepithelial neoplasia; HPV, human papillomavirus; SCC, squamous cell carcinoma; CIN 1, mild cervical 
intraepithelial neoplasia; CIN 2, moderate cervical intraepithelial neoplasia; CIN 3, severe cervical intraepithelial neoplasia; CIS, carcinoma “in situ”.
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In  addition, a general physical and gynecological examina-
tion was performed. These procedures were carried out over a 
period of approximately three years, which was a requirement in 
order to discharge the patients from the algorithm and to return 
them to their corresponding PHC.
The average time interval between the collection of the first 
ASCUS report and the second phase (diagnosis through a rep-
etition of atypical Pap tests) was 194.34 days. The time from this 
first report to the third phase (diagnostic confirmation) was 
402.89 days; the time to the fourth phase (treatment) was 536.75 
days; and the time to the fifth phase (post-treatment follow-up) 
was 841.51 days.
At the end of the follow-up period, the cohort of 446 female 
with a first ASCUS report achieved the following results (exclud-
ing the 83 women who had been lost from the follow-up): nega-
tive for neoplasia (n = 313) (86.2%); and negative for neoplasia 
plus presence of HPV (n = 7) (1.9%). Neoplastic lesions of vari-
ous degrees were presented by 43 patients (11.9%). Cytological-
colposcopic-histological diagnostic procedures were used to 
confirm normal results, and histological diagnostic procedures 
were used to confirm lesions (Figure 4). 
DISCUSSION
Debate continues regarding what the single strategy for opti-
mal management of patients with ASCUS cytological reports 
might be.1-3 In our study, the population affected by this uncer-
tain situation had a wide age range (17-88 years), which exceeded 
the limits (25-64 years) of the National Cervical Cancer Program. 
However, our age ranges were similar to those in Iraq, the United 
States and Turkey, in that the ages of females with a first atypical 
Pap result go from adolescence to adulthood.17-19
The clinical management strategies for these women, i.e. 
those for whom referral to specialists or a Cervical Pathology 
Unit for first atypical Pap results is proposed by the algorithm, in 
accordance with the Bethesda 2001 classification, are outlined in 
the National Clinical Guidelines.6 At the diagnosis stage, the 
ASCUS cytological report is repeated, as indicated in our National 
Guidelines. This is also highly recommendable and advisable 
according to the various clinical guidelines of some other coun-
tries such as the United States, France and England.1,12,13,20 At this 
stage in Chile, diagnoses of HPV are not taken into consider-
ation. In conformity with the standards established for the diag-
nosis stage, most of the women with first ASCUS cytological 
reports underwent a new Pap test six months later, in accordance 
with the clinical guideline regulation. Only 4.9% (18/363 smears) 
had the same atypical result. These data are similar to those 
found in the study by Tewari et al., in which 604 ASCUS cyto-
logical reports were repeated over a six-month period and the 
same results were only obtained in 3.8% of the smears.21 In Chile, 
Fanny et al. carried out an epidemiological study on 154 women 
with ASCUS reports and concluded that the appropriate length 
of time necessary before having the exam repeated is 6.4 months. 
With this time interval, outcomes of normal results or lesions 
were demonstrated.22 
In our study, we found that 85.1% of the patients achieved 
normal results (n = 301), which was similar to the outcome of 
Tewari et al., in which the rate of regression to normalcy was 
73.3%.21 The standard to follow according to what is indicated 
by the primary atypical Pap algorithm, is for patients to return 
to their PHC to continue with regular screenings, as established 
by the National Program for Research and Control of Cervical 
Cancer in Chile. 
Alternatively, abnormal results (n  =  62) were sent to the 
CPU to continue with completion of colposcopy, which is a pro-
cedure established in the national algorithm. This decision is 
similar to the “acceptable” conduct advocated by the American 
Society for Colposcopy and Cervical Pathology, in which it is 
recommended to “repeat the Pap smear and colposcopy only 
Biopsy
1 Neg + HPV
5 CIN 2
4 CIN 3
6 CIN 1 + HPV
13 CIN 2 + HPV
4 CIN 3 + HPV
4 CIN 1 + HPV
1 CIN 1 + HPV
2 SCC 1 CIN 1 + HPV
Cryotherapy CKC HT CT + RT Polypectomy
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Figure 3. Treatment stage: according to the histological result.
CKC, cold-knife cone biopsy; HT, hysterectomy; CT + RT, chemotherapy and radiotherapy; Neg, negative for intraepithelial lesion; CIN 1, mild cervical 
intraepithelial neoplasia; CIN 2, moderate cervical intraepithelial neoplasia; CIN 3, severe cervical intraepithelial neoplasia; HPV, human papillomavirus; 
SCC, squamous cell carcinoma; CIS, carcinoma “in situ”.
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as a reference if the second result is ASCUS+.”1,23 Following the 
aforementioned standard, 53 of our patients immediately 
underwent this examination: patients who met the cytological 
condition of ASCUS+ (30 low-grade lesions and 23 high-grade) 
and another nine women with clinical symptoms. Fulfillment of 
this colposcopic procedure was suggested by Kabaca et al., who 
recommended an aggressive conduct of immediate colposcopy 
when a first atypical Pap was presented. They conducted a study 
involving 205 female with ASCUS Pap smear results, 9.75% 
of whom presented CIN 2+ lesions.20 However,  other studies 
have indicated that immediate colposcopy should only be per-
formed on HSIL+ lesions, given that minor lesions return spon-
taneously.24 We recommend that colposcopy should only be 
performed when there are two consecutive atypical Pap tests, 
because with these two results, we were able to demonstrate 
85.5% of the lesions, whereas colposcopy performed imme-
diately after the first atypical Pap test only showed 16.9% of 
the lesions. 
An exploratory colposcopy examination is considered, within 
the algorithm, to be a procedure that would allow a decision to 
carry out a directed biopsy.6 Although the standards do not estab-
lish any necessity for a biopsy in cases of negative results, this 
was carried out in the majority of our cases (9 out of 13) and 
yielded two cases of a minor lesion (CIN 1). In cases of inconclu-
sive results, a biopsy was also performed, yielding the following: 
Neg (n = 2) and CIN 2 (n = 1). 
The diagnostic confirmation stage was followed by the treat-
ment stage, which was conducted in accordance with the literature.
Lastly, the follow-up was conducted on 363 cases in our 
cohort of women with a first ASCUS report. The 83 cases that 
were lost from the follow-up were not taken into consider-
ation. The women who returned for follow-up evaluation pre-
sented a LSIL rate of 3.6% and a HSIL rate of 11.6%, both of 
which are within the range of results from other studies over the 
last five years, from 0% to 47.1% for LSIL and 0.8% to 8.6% for 
HSIL.17,18,25,26 It is clear that the percentage of HSIL lesions was 
higher than in the literature, but the cause is hard to explain. 
The  diagnostic confirmation of these lesions was achieved by 
completion of a biopsy. This procedure was the same as has been 
established in the scientific literature, which considers that the 
efficiency of cervical cytological screening is determined through 
histological verification.19
These procedures that have been established through algo-
rithms possess strengths and weaknesses. We consider that their 
strength lies in the contribution that they have made towards 
resultant lower rates of cervical cancer mortality in Chile. 
We  consider that the lack of classification of the HPV virus is 
a weakness, given that there are no studies to support the algo-
rithm regarding HPV. 
These algorithm-guided behaviors have contributed towards 
lower rates of cervical cancer mortality in Chile, which are among 
the lowest in Latin America.27,28 
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Figure 4. Follow-up results among women with ASCUS, and diagnostic confirmation procedure.
Neg, negative for intraepithelial lesion; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; CIN 1, mild cervical intraepithelial neoplasia; 
CIN 2, moderate cervical intraepithelial neoplasia; CIN 3, severe cervical intraepithelial neoplasia; SCC, squamous cell carcinoma.
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CONCLUSIONS
The clinical management observed through our monitoring 
shows that cases of a first ASCUS cytological report are managed 
in a traditional manner, in that it takes into consideration screen-
ing, diagnosis, diagnostic confirmation, treatment and post-
treatment evaluation stages.
We agree with repetition of the first atypical Pap test six 
months later because this enables definition of the results.
The rate of regression to normality among the ASCUS cases 
was 85.1%, which confirms that Pap tests should only be repeated 
as part of the surveillance pattern.
We agree that women should be sent for immediate colpos-
copy whenever there are two consecutive atypical results, because 
of the high percentage of lesions (85.5%).
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